Onco Actu du 26 juin 2017

	3.3 Prévention - Vaccins
European Court OKs Vaccine Lawsuits Lacking Proof [The Scientist] Vaccine experts are slamming the court’s reasoning for the ruling, which was made in response to J.W., a French citizen, suing Sanofi Pasteur in 2006 after he was diagnosed with multiple sclerosis a year after receiving one of the company’s hepatitis B vaccines.
	4.7 Dép., diag. & prono. - Col de l'utérus
HPV testing leads to earlier detection and treatment of cervical pre-cancer [Queen Mary University of London] Women who receive human papillomavirus (HPV) testing, in addition to a pap smear, receive a faster, more complete diagnosis of possible cervical precancer, according to a study of over 450,000 women by Queen Mary University of London (QMUL) and the University of New Mexico (UNM) Comprehensive Cancer Center.
	5. Traitements
Existing drugs could benefit patients with bone cancer, genetic study suggests [Sanger Institute] In the largest genetic sequencing study of osteosarcoma to date, scientists discovered that 10 per cent of patients with a genetic mutation in particular growth factor signalling genes may benefit from existing drugs, known as IGF1R inhibitors.
	5.10 Traitements - Essais
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) [Novartis] At four years, OS was 51.4% in the Rydapt arm, compared with 44.3% in the placebo arm.
	5.12 Immunothérapies
Tumour characteristics could predict immunotherapy success in lung cancer [Cancer Research UK] To make sure that these important drugs reach patients who are most likely to benefit from them, Swanton says, future studies need to look into the role of the number of genetic faults within a tumour and select patients whose PD-L1 levels are above a certain level.
	5.12.5 Immunothérapies - Pharma
Behind big pharma's race to develop the next wave of cancer therapy [The Telegraph] Then there’s the cost, put at around £150,000 a year per patient for a typical IO treatment. Will the NHS and other country’s health services be willing to pay this?
	5.3 Traitements - FDA, EMA, NICE...
Decision on EMA Relocation Set for November, Council Agrees on Bidding Procedure [RAPS] In particular, the procedure says potential hosts should be able to provide "appropriate" offices that are near an airport that offers convenient flights from the capitals of the other member states and have adequate multi-lingual schools for the children of agency staff.
	5.3.4 Traitements - AMM (FDA, EMA)
Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer [Bayer] Approval could provide first treatment advance in nearly a decade.
AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma [Aveo] The EC, which typically adheres to the recommendation of the CHMP, but is not obligated to do so, is expected to make its final decision in about 67 days.
Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor [Novartis] After nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared to 16.0 months for letrozole alone.
	5.9.3 EHA
Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting [Takeda] Early studies of weekly and twice-weekly ixazomib plus lenalidomide and dexamethasone demonstrate deep responses after induction, with deepening responses seen after single-agent ixazomib maintenance.
Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial [BMS] The extended follow-up data is the longest of an Immuno-Oncology agent in relapsed/refractory multiple myeloma.
Positive Phase 1b Data for NewLink Genetics' IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain [NewLink Genetics] These data indicate indoximod does not appear to add significant toxicity to standard therapy for patients with newly diagnosed AML, and no regimen-limiting toxicities (RLT) have been observed to date.
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma [Roche] Longer follow-up showed sustained benefit in progression-free survival of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatment regardless of chemotherapy regimens.
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers [Roche] Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia, including those with 17p chromosomal deletion.
	6.10.1 Politiques (USA)
ASH President Expresses Disappointment with Senate Health Care Bill [ASH] Our lawmakers’ continued efforts to scale back health protections afforded to Americans runs directly counter to ASH’s mission of furthering prevention, diagnosis, and treatment of some of the most serious and costly disorders patients face.
	6.6 Publications
PubPeer Launches Updated Site [The Scientist] New features include increased security of user anonymity.
	6.7.3 DMP
Electronic health records in Sweden—how can we go from transparency to collaboration? [BMJ Blogs] Once patients have the basic right of access (equally for all, not based on each care provider’s decision), how can we make this a tool for collaboration? I would like to propose two important steps which require both a change in practice, and further research and development.